Making a meaningful difference

Turning scientific innovation into meaningful impact

Zymeworks is a royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases. Through our proprietary platforms, deep scientific expertise, and global partnerships, we build and manage a portfolio of healthcare assets designed to deliver long-term impact across multiple therapeutic indications.

Partner with us

Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.

News

March 30, 2026

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

March 24, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

March 18, 2026

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting